Heidelberg Pharma AG reported today on its operational progress as well as on the Group’s financial figures for the first nine months of fiscal year 2024 (1 December 2023 – 31 August 2024).
– HDP-101 clinical trial in Europe and US continues with adjusted protocol and dose optimization on track; sixth patient cohort dosed at 90 µg/kg and patients are still on treatment
– Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty
– New clinical data with HDP-101 presented at the International Myeloma Society (IMS) Annual meeting; one patient in complete remission
– Two R&D webinars with Key Opinion Leaders planned for October
– Guidance adjusted